BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 26163633)

  • 21. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for ischemic stroke in patients with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms.
    Wen S; Zhang W; Fei Y; Guan K; Zhao H; Song P; Ye X; Pan Y
    J Clin Neurosci; 2024 Jul; 125():159-166. PubMed ID: 38815302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
    Brière J
    Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical and genetic characteristics of young patients with myeloproliferative neoplasms].
    Zhang MY; Bao M; Shi DY; Shi HX; Liu XL; Xu N; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):193-201. PubMed ID: 37356980
    [No Abstract]   [Full Text] [Related]  

  • 25. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms.
    Wang J; Ishii T; Zhang W; Sozer S; Dai Y; Mascarenhas J; Najfeld V; Zhao ZJ; Hoffman R; Wisch N; Xu M
    Leukemia; 2009 Sep; 23(9):1577-86. PubMed ID: 19387466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
    Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
    Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Our experience with detection of JAK2 mutations in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative disorders].
    Burjanivová T; Marcinek J; Minárik G; Lasabová Z; Szépe P; Balhárek T; Vanochová A; Plank L
    Cesk Patol; 2011 Jul; 47(3):115-7. PubMed ID: 21887928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders.
    Ayad MW; Nafea D
    Genet Test Mol Biomarkers; 2011; 15(1-2):17-21. PubMed ID: 21034166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
    Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
    Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current treatment concepts of Philadelphia-negative MPN.
    Wolf D; Rudzki J; Gastl G
    Curr Cancer Drug Targets; 2011 Jan; 11(1):44-55. PubMed ID: 21062242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.
    Boveri E; Passamonti F; Rumi E; Pietra D; Elena C; Arcaini L; Pascutto C; Castello A; Cazzola M; Magrini U; Lazzarino M
    Br J Haematol; 2008 Jan; 140(2):162-8. PubMed ID: 18028479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.
    England JT; Szuber N; Sirhan S; Dunne T; Cerquozzi S; Hill M; Villeneuve PJA; Ho JM; Sadikovic B; Bhai P; Krishnan N; Dowhanik S; Hillis C; Capo-Chichi JM; Tsui H; Cheung V; Gauthier K; Sibai H; Davidson MB; Bankar A; Kotchetkov R; Gupta V; Maze D
    Leukemia; 2024 Mar; 38(3):570-578. PubMed ID: 38321107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
    Zhu JF; Liu Y; Liu P; Jia MF; Cheng J; Zhao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):916-20. PubMed ID: 21867614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype-phenotype interactions in the myeloproliferative neoplasms.
    Godfrey AL; Green AR
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):993-1015. PubMed ID: 23009934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.